Morphic Holding, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Praveen P. Tipirneni
- Full Time Employees
- 128
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 35 Gatehouse Drive, A2 Waltham MA United States of America 02451
- IPO Date
- Jun 27, 2019
- CIK
- 0001679363
- Website
- morphictx.com
- Similar Companies
- Business
- Morphic Holding, Inc. (MORF) is a biopharmaceutical company that discovers and develops oral small-molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune conditions such as inflammatory bowel disease (IBD), cardiovascular and metabolic diseases, fibrosis, and cancer; its lead product candidate, MORF-057, is a selective oral α4β7 integrin inhibitor currently advancing in two Phase 2 clinical studies for ulcerative colitis and one Phase 2 study for Crohn's disease; additional pipeline candidates leverage the proprietary MInT (Morphic Integrin Technology) Platform, which enables targeting of all 24 human integrin types with inhibitors and activators derived from a library exceeding 16,000 unique compounds. The company utilizes its expertise in integrin biology, structural analysis, and therapeutic design to address limitations of prior intravenous or topical integrin therapies, focusing on patient populations with unmet needs in gastroenterology, immunology, and beyond. Founded in 2014 and headquartered in Waltham, Massachusetts, Morphic Holding operates primarily in the United States with a global development footprint for its clinical programs. In 2024, Eli Lilly and Company completed its $3.2 billion acquisition of Morphic Holding at $57 per share through a tender offer and subsequent merger, integrating Morphic as a wholly owned subsidiary to bolster Lilly's immunology portfolio with oral integrin therapies for IBD and other indications.
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Clients to Contact the Firm!
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!
MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!
MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!
MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!